Triple cholesterol pill cocktail could beat standard care after heart attack
NCT ID NCT07508254
First seen Apr 04, 2026 · Last updated Jun 23, 2026 · Updated 11 times
Summary
This study will test whether taking three cholesterol-lowering drugs together (atorvastatin, ezetimibe, and bempedoic acid) works better than the usual two-drug combination for people who have recently had a heart attack or unstable chest pain (acute coronary syndrome). About 120 adults will be randomly assigned to either the triple or dual therapy for 3 months. The main goal is to see which group has a greater drop in 'bad' LDL cholesterol, and to check for any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERCHOLESTEROLEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Punjab Institute of Cardiology
Lahore, Punjab Province, 56000, Pakistan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Atorvastatin, ezetimibe, and bempedoic acid (three cholesterol-lowering drugs)
What this could lead to
If it works, this could show that a three-drug combination lowers 'bad' cholesterol more effectively than the usual two-drug approach after a heart attack or related event.
What could go wrong
This is a small, early-phase trial (120 people) that hasn't started yet. The triple therapy may cause more side effects or not prove significantly better than the standard dual therapy.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.